Home/Hedge Fund Intelligence/Emerging Markets Healthcare Partners
Hedge FundDelawareMaster fund3(c)(1)

Emerging Markets Healthcare Partners

Estimated returns, assets and SEC record

Managed by Exome Asset Management LLC · New York · in Form ADV since 2019 Also runs 1 other fund we cover

Emerging Markets Healthcare Partners is a Delaware hedge fund managed by Exome Asset Management LLC. It reported gross assets of USD 79m in the Form ADV filed 28 March 2024. Hedge funds do not file their returns with the SEC. From what this fund and its manager do file, PPLI Vortex estimates that it returned about 64.3% in 2025, with a likely range of -16.9% to 145.4%.

Unqualified audit opinionIndependent administratorPCAOB-registered auditor
2025, estimated+64.3%range -16.9% to 145.4% · grade D-13F · estimated for the manager as a whole
Latest quarter+10.9%to 30 Jun 2026 · range -0.7% to 22.6%
Gross assetsUSD 79mForm ADV · filed 28 Mar 2024
Minimum investmentUSD 1mForm ADV, Schedule D
Investors39beneficial owners
In SEC filings since2019first Form ADV listing

Compiled by PPLI Vortex from SEC filings · Hedge Fund Intelligence, PPLI.com · updated · about PPLI Vortex

Return figures are PPLI.com estimates from public SEC filings, not numbers reported by the fund. Not investment advice. Important information

PPLI.com
Hedge Fund Rating
Rating in preparation
We publish a rating only once a fund's file has been through editorial review. This fund is in the queue.
Returns
Risk
SEC record and governance
Fees and terms
Fit for a PPLI policy
Editorial assessment from SEC filings
Reviewed every quarter
About the rating
D
Confidence grade D-13F

We rebuild the manager's long positions from Form 13F and scale them to how hedge funds of this kind have behaved. Shorts, leverage and fees are not visible.

How the grades work

A and B are computed from public filings. C, C-est and D-est are estimates built on what registered funds that hold the fund report. D-13F is an estimate from the manager's 13F long book. Every figure on this page is shown with its range and grade.

Quarter by quarter

Emerging Markets Healthcare Partners, one quarter at a time

How the estimate moved through each year since 2021, with the yearly figure alongside.

Each cell is our estimate for that quarter, with the range it could fall in underneath. The last column is the figure for the full year. It is worked out on its own from the year's filings, so the four quarters will not multiply out to it exactly. Every figure here is graded D-13F. The quarters are estimated for the manager as a whole from its 13F long book and shown on each of its funds.

YearJan to MarApr to JunJul to SepOct to DecFull year
2026+3.0%-8.7% to 14.6%+10.9%-0.7% to 22.6%not yet filednot yet filed+14.1%-9.2% to 37.4%, to 30 Jun
2025−4.9%-16.5% to 6.8%+18.2%-0.6% to 36.9%+12.6%0.2% to 25.0%+25.3%11.6% to 39.0%+64.3%-16.9% to 145.4%
2024+9.2%-2.9% to 21.3%−0.9%-12.9% to 11.0%+4.7%-7.4% to 16.9%+0.2%-11.6% to 12.0%+16.5%-20.5% to 53.4%

Estimates by PPLI Vortex from public SEC filings, not figures reported by the fund. n/a means the filings do not support a figure for that quarter.

Next: what the manager holds
Holdings

52 positions, with 45% of the money in the ten largest

Emerging Markets Healthcare Partners does not publish what it owns. Its manager does: every quarter Exome Asset Management LLC lists its U.S.-listed stocks and options on Form 13F. The list covers every account the firm runs, not this fund alone, and leaves out short positions, bonds, swaps and shares listed outside the United States. Most of what the firm's hedge funds hold is in this book, so it is a fair picture of the fund.

Value reportedUSD 162m
Positions52
In the ten largest45%
Largest positionGuardant Health, Inc., 6.2%
Holdings as of30 June 2026
The 15 largest positions

Share is of the total value reported. Options are shown at the value of the shares they cover. Choose a company to see which other managers report it.

#CompanyValueShare of the book
1 Nasdaq: GHHeld by 66 of the 720 managers we trackUSD 10m6.2%
2 Nasdaq: PRAXNewHeld by 42 of the 720 managers we trackUSD 9.1m5.6%
3 Nasdaq: TGTXHeld by 27 of the 720 managers we trackUSD 9.1m5.6%
4 Nasdaq: COGTHeld by 57 of the 720 managers we trackUSD 8.1m5.0%
5 Nasdaq: IONSHeld by 44 of the 720 managers we trackUSD 7m4.3%
6 NYSE: LLYHeld by 106 of the 720 managers we trackUSD 6.6m4.1%
7 Nasdaq: ABVXADSHeld by 56 of the 720 managers we trackUSD 6.2m3.9%
8 Nasdaq: ALMSHeld by 29 of the 720 managers we trackUSD 5.8m3.5%
9 Nasdaq: CYTKNewHeld by 57 of the 720 managers we trackUSD 5.1m3.2%
10 Nasdaq: ELVNHeld by 38 of the 720 managers we trackUSD 5.1m3.1%
11 Nasdaq: VERAClass AHeld by 38 of the 720 managers we trackUSD 4.2m2.6%
12 NYSE: UNHHeld by 107 of the 720 managers we trackUSD 4m2.5%
13 Nasdaq: TXGClass A ComHeld by 31 of the 720 managers we trackUSD 3.9m2.4%
14 Nasdaq: NTRAHeld by 61 of the 720 managers we trackUSD 3.7m2.3%
15 Nasdaq: QUREHeld by 45 of the 720 managers we trackUSD 3.7m2.3%
Guardant Health, Inc.: 6.2%Praxis Precision Medicines, Inc.: 5.6%TG Therapeutics, Inc.: 5.6%Cogent Biosciences, Inc.: 5.0%Ionis Pharmaceuticals Inc: 4.3%ELI LILLY & Co: 4.1%Abivax S.A.: 3.9%Alumis Inc.: 3.5%Positions 9 to 15: 18.4%The rest of the book: 43.4%52POSITIONS
How the book is split
  • Guardant Health, Inc.6.2%
  • Praxis Precision Medicines, Inc.5.6%
  • TG Therapeutics, Inc.5.6%
  • Cogent Biosciences, Inc.5.0%
  • Ionis Pharmaceuticals Inc4.3%
  • ELI LILLY & Co4.1%
  • Abivax S.A.3.9%
  • Alumis Inc.3.5%
  • Positions 9 to 1518.4%
  • The rest of the book43.4%
Next: the manager's other funds
The manager's funds

Exome Asset Management LLC runs 2 funds we cover

Every fund of Exome Asset Management LLC on PPLI.com

2 funds, largest first by gross assets. Returns are PPLI Vortex estimates; each has its own range on that fund's page. Figures graded D-13F are one estimate made for the manager as a whole and shown on each of its funds, so they are not separate readings and should not be compared with one another.

FundSinceGross assetsStrategy202120222023202420252026part year
Worldwide Healthcare Partnersmaster · United States2020formed, per Form DUSD 87mHealthcarefrom the fund's namen/an/an/a+16.5%+64.3%+14.1%
Emerging Markets Healthcare Partnersthis page2020formed, per Form DUSD 79mHealthcare and Emerging marketsfrom the fund's namen/an/an/a+16.5%+64.3%+14.1%

The 2026 column covers the part of the year the filings reach so far; the fund's own page gives the end date. SEC filings do not state a strategy for each fund. The column shows what the fund's own name says, or failing that how the manager describes itself, and says which. A year of formation is shown where a Form D gives one; otherwise it is the year the fund first appears in the SEC's Form ADV data.

Next: returns year by year
Returns year by year

About 64% in 2025, with a range too wide to call against the index

The SEC filings of Emerging Markets Healthcare Partners carry no return figures. These are our estimates, each with the range we think the true figure falls in and a grade for how it was reached.

Gold bars are the fund. The thin line on each bar is the range we think the true figure falls in. Grey bars are the S&P 500 total return in U.S. dollars, dividends reinvested, over the same calendar years. It is there as a picture of the market, not as the benchmark this fund sets itself.

0%50%100%150%202416.5%202564.3%2026 to date14.1%
PeriodReturnLikely rangeGradeS&P 500Difference
202416.5%-20.5% to 53.4%D-13F25.0%-8.5 pts
202564.3%-16.9% to 145.4%D-13F17.9%+46.4 pts
2026 to 30 Jun14.1%-9.2% to 37.4%D-13F

These figures are an estimate for the manager as a whole. The same estimate appears on a larger fund of Exome Asset Management LLC, because Form 13F does not split positions by fund.

Returns are before the fees an investor pays unless they come from a public holder's reported value, which is after the fund's own fees.

USD 100 in Emerging Markets Healthcare Partners against the S&P 500start of 2024 = 100

The gold line compounds our yearly figures. The shaded area is where the line would run if every year came in at the low or the high end of its range. The grey line is the S&P 500 with dividends.

100200300400StartEnd 2024End 2025Fund 191S&P 500 147

By the end of 2025, USD 100 in the fund had become about USD 191 by our estimate, against USD 147 in the index.

What an investor would have kept, 2024 to 2025

Takes our yearly figures for Emerging Markets Healthcare Partners and shows what is left after fees and tax, next to the same money inside a PPLI policy. Change any of the numbers. Our 13F-based figures price the manager's long book and take no fees off, so the tool treats them as before fees. Public filings do not settle that, and they do not give the fund's terms either. The fees are yours to set; put both at 0 to read the estimate as if it were already after fees.

Emerging Markets Healthcare Partners, as estimatedour yearly figures compounded, before fees and taxUSD 1.9m
After the fund's feeswith the fees you entered, charged above a high-water markUSD 1.7m
After tax, held directlygains taxed every year at the rate you enteredUSD 1.4m
Held inside a PPLI policyno yearly tax on gains inside a policy that keeps to the rules, less the yearly policy costUSD 1.6m
S&P 500 with dividendsthe index over the same years, before taxUSD 1.5m
Each year: as estimated, after fees, after tax and inside a policy
YearAs estimatedAfter feesAfter taxInside a policyS&P 500
202416.5%12.0%7.1%10.9%25.0%
202564.3%50.2%29.7%48.7%17.9%

The fee defaults of 1.5% and 20% are common hedge fund terms, not this fund's. The tax rate of 40.8% is the top U.S. federal rate on short-term gains with the net investment income tax; a fund whose gains are mostly long-term would be taxed at 23.8%. State tax is not included. Policy costs differ by carrier and by the size of the policy. If every year had come in at the bottom or the top of our range, the first line would read USD 661,000 or USD 3.8m. An illustration, not advice.

Returns by period

Annualised where the period is longer than a year. The range compounds the low and high ends of each year.

PeriodEmerging Markets Healthcare PartnersLikely rangeS&P 500Difference
Latest year202564.3%-16.9% to 145.4%17.9%+46.4 pts
Compare with other funds

Type the name of any fund we estimate and it joins the table. Up to five at a time. Every figure is an estimate; open a fund to see its range and grade.

Fund20212022202320242025
Emerging Markets Healthcare Partners16.5%64.3%
S&P 500 with dividends28.7%-18.1%26.3%25.0%17.9%
Next: where the numbers come from
Where the numbers come from

Built from the manager's quarterly 13F filings

A hedge fund reports almost nothing about itself. Others report about it, and that is what we read.

Exome Asset Management LLC's disclosed U.S. long book

Every quarter the manager lists its U.S. listed long positions on Form 13F, most recently USD 162m for 30 June 2026. Pricing those positions through each year gives the return of the long book alone. It covers all the manager's clients, not this fund, and leaves out shorts, leverage, non-U.S. holdings and fees. The long book is most of what the manager's hedge funds hold, so it says a good deal about this fund.

20242025
13F long book9.0%103.8%
S&P 50025.0%17.9%
0%20%40%60%80%100%20242025
Next: size and investors
Size and investors

USD 79m in gross assets, down from USD 100m reported in 2022

The fund in Form ADV, Schedule D

What the adviser reported about this fund in the filing of 28 March 2024. Gross assets are the fund's total assets before borrowings are deducted. They are not net assets and say nothing about performance.

Gross asset valueUSD 79m
Minimum investmentUSD 1m
Beneficial owners39
Owned by the adviser and its people77%
Owned by funds of funds0%
Owned by non-U.S. persons9%
Investor eligibility3(c)(1): up to 100 investors
DomicileDelaware
StructureMaster fund
Full legal nameEmerging Markets Healthcare Partners LLC
SEC private fund ID805-5624001535
Gross assets over timeUSD m, by the year the figure was filed

Each bar is the gross asset value in that year's Form ADV. An annual filing reports the previous fiscal year end, so each bar describes the year before. A change in gross assets is not a return: money coming in, money going out, borrowing and performance all move it, and the filings do not say which.

201942.5202047.0202191.22022100202380.1202478.8
Master and feeder funds

Investors often enter through a feeder that passes their money to a master fund, where the trading happens.

  • Feeder: Emerging Markets Healthcare Partners International Ltd.
Next: who audits and administers it
Service providers

Audited by CohnReznick LLP, administered by Hedgeserv (Cayman)

An outside auditor and an administrator that is not part of the manager are the two checks an investor can verify from public filings.

Named by the adviser in Form ADV Schedule D, questions 23 to 28, in the filing of 28 March 2024.

RoleFirmWhereAs stated in the filing
AuditorCohnReznick LLPNew York, New YorkIndependent, pcaob registered
AdministratorHedgeserv (Cayman) LtdGrand Cayman, Cayman IslandsNot related to the adviser
Prime brokerJefferies LLCNew York, New YorkAlso custodian
CustodianJ.P. Morgan Securities LLCNew York, New YorkNot related to the adviser
CustodianStandard Chartered Bank (Hong Kong) LimitedKwun Tong, Hong KongNot related to the adviser
CustodianJefferies LLCNew York, New YorkNot related to the adviser
MarketerFairview Securities, Inc.Westport, ConnecticutNot related to the adviser
Audit and valuation
Audited every yearYes
Statements under U.S. GAAPYes
Audited statements sent to investorsYes
Share of assets valued by an outside party100%
General partner, manager or directors

Form ADV Schedule D, question 3.

  • Exome Asset GP LLC
Next: how the fund is offered
The offering, from Form D

Offering filed by a related vehicle

The Form D linked to this fund was filed by Emerging Markets Healthcare Partners International Ltd., a related vehicle of the same manager, often the feeder or offshore twin through which investors come in. The figures below describe that vehicle.

Issuer on the filingEmerging Markets Healthcare Partners International Ltd.
Total sold to dateUSD 4.3m
Investors to date11
Minimum investmentUSD 1m
Date of first sale1 September 2020
Exemptions claimed06b, 3C, 3C.1
EntityOther
JurisdictionCayman Islands
Form D filings on EDGAR8
Next: the manager
The manager

Exome Asset Management runs 2 funds we cover

AdviserExome Asset Management LLC
StatusSEC-registered adviser
Registered since28 July 2021
SEC number801-121896
CRD number304585
OfficeNew York, NY
Latest Form ADV27 March 2026
Brochure (Part 2A)27 March 2026
In the manager's own words

What Exome Asset Management LLC says about itself on exomeasset.com, read on 14 November 2026. A sentence in quotation marks is the firm's own; the rest is in our words. These are the firm's statements, not ours, and we have not checked them. They describe the firm as a whole, not this fund.

What it says it doesHealthcare and biotechnology and emerging markets
Offices it listsNew York
LinkedInCompany page
On the siteAn investor login
The manager at a glance

Gross assets are added across the funds we cover and count a master fund and its feeders separately, so they overstate the money the firm runs.

Funds of this manager on PPLI.com2
Their gross assets togetherUSD 166m
With return figures2
U.S. long book on Form 13FUSD 162m
Positions in that book52
Form ADV filings that list this fund14
The paper trail

Dates taken from the filings themselves.

  • 28 Aug 2019 First Form ADV in the SEC's bulk data to list the fund
  • 28 Jul 2021 Exome Asset Management LLC registered with the SEC
  • 28 Mar 2024 Latest Form ADV listing the fund in the bulk data
  • 27 Mar 2026 Latest Form ADV of the manager
  • 14 Aug 2026 Latest Form 13F of the manager, for 30 June 2026
  • 23 Oct 2026 Latest Form D of the related vehicle
Next: holding it inside a policy
Inside a policy

Can Emerging Markets Healthcare Partners be held inside a PPLI policy?

Not directly, for a U.S. taxpayer. U.S. tax rules test what a policy holds for diversification, and a fund that is also sold to investors outside insurance accounts counts as a single holding and is not looked through to what it owns. Choosing such a fund yourself also raises the investor-control question the IRS has ruled on.

In practice a U.S.-compliant policy reaches a hedge fund strategy through an insurance-dedicated fund, whose interests are held by insurers' separate accounts with a few exceptions the regulations allow, or through a separately managed account run for the insurer. Policies issued outside the United States for people who are not U.S. taxpayers follow the rules of their own jurisdiction, and those differ.

Some managers run an insurance-dedicated version of their strategy. Where they do, gains that a taxable investor would pay tax on each year can build up inside the policy, as long as the policy keeps to the rules. We have no record that Exome Asset Management LLC offers one. That is a gap in our file, not a finding that it does not. We keep a directory of insurance-dedicated funds and the managers behind them.

Insurance-dedicated funds on PPLI.com   Hedge fund strategies inside PPLI

The diversification test, on the manager's reported book

The investments inside a policy must be spread: no more than 55% in one holding, 70% in two, 80% in three and 90% in four. This table runs that test on the positions Exome Asset Management LLC reported on Form 13F for 30 June 2026. It is a rough guide only, since an insurance-dedicated version would hold the whole strategy, shorts included.

MeasureLimitThis bookResult
The largest holding55%6%Within the limit
The two largest70%12%Within the limit
The three largest80%17%Within the limit
The four largest90%22%Within the limit

On this evidence the long book is spread widely enough.

Next: notes on this file
Notes

What the filings leave open

What we would ask the manager

Questions the filings raise and cannot answer.

  • You and your people own 77% of the fund. What would it mean for outside investors if you took that money out?
  • Our estimate rests on your long book alone. What did the short book, leverage and trading inside the quarter add or take away?
  • Do you offer this strategy as an insurance-dedicated fund or a separately managed account for insurers?
Changes to this file
  • 13 Nov 2026 File opened from SEC filings
  • 14 Nov 2026 Manager's website read and its facts added
  • 15 Nov 2026 Page revised.
The manager's response

Not yet received. Exome Asset Management LLC can ask us to check any fact on this page and can send a response, which we will publish here unedited. Write to the editor.

Next: questions
Questions

Questions about Emerging Markets Healthcare Partners

What has Emerging Markets Healthcare Partners returned?

The SEC filings of Emerging Markets Healthcare Partners carry no return figures. PPLI Vortex estimates, from SEC filings: 16.5% in 2024, 64.3% in 2025, 14.1% in 2026 to 30 Jun. Each estimate has a range; for 2025 it is -16.9% to 145.4%.

How reliable are the return figures for Emerging Markets Healthcare Partners?

They are estimates, not figures reported by the fund. Each one is shown with a range and a grade. The grade for the latest figure is D-13F: estimated from the manager's Form 13F long book. Shorts, leverage, trading within a quarter and fees are not visible in public filings.

What does Emerging Markets Healthcare Partners invest in?

Emerging Markets Healthcare Partners does not publish its holdings. Its manager, Exome Asset Management LLC, reported 52 U.S.-listed positions worth USD 162m on Form 13F for 30 June 2026. The largest were Guardant Health, Inc., Praxis Precision Medicines, Inc., TG Therapeutics, Inc. The filing covers all of the manager's accounts and excludes short positions.

How big is Emerging Markets Healthcare Partners?

Emerging Markets Healthcare Partners reported gross assets of USD 79m in the Form ADV filed 28 March 2024. Gross assets are total assets before borrowings are deducted, so the figure is larger than what investors have put in when the fund uses leverage.

What is the minimum investment in Emerging Markets Healthcare Partners?

USD 1m, as stated in Form ADV Schedule D. Managers can and do waive minimums.

Who audits and administers Emerging Markets Healthcare Partners?

The auditor is CohnReznick LLP. The administrator is Hedgeserv (Cayman) Ltd. These are the firms named in the Form ADV filed 28 March 2024.

What does Exome Asset Management LLC invest in?

On its website the firm writes mainly about healthcare and biotechnology and emerging markets. That is how it describes itself, and it covers the whole firm, not Emerging Markets Healthcare Partners alone.

How do I contact Exome Asset Management LLC?

The firm can be reached by email at [email protected], the details it gives on exomeasset.com. PPLI.com is not connected to the firm and cannot pass messages on.

Where is Exome Asset Management LLC based?

Its website lists New York. The address on its SEC filing is in the manager section above.

Who manages Emerging Markets Healthcare Partners?

Exome Asset Management LLC, CRD number 304585. It is an SEC-registered adviser.

Can Emerging Markets Healthcare Partners be held inside a PPLI policy?

Not directly, for a U.S. taxpayer. Under U.S. tax rules a policy reaches a hedge fund strategy through an insurance-dedicated fund or a separately managed account run for the insurer, not through a fund that is also sold to other investors. Policies issued outside the United States follow their own rules. We have no record that Exome Asset Management LLC offers an insurance-dedicated version, so an investor would need to ask the firm.

What did Emerging Markets Healthcare Partners return each quarter?

Emerging Markets Healthcare Partners does not file quarterly returns with the SEC. PPLI Vortex estimates 12.6% in the third quarter of 2025, 25.3% in the fourth quarter of 2025, 3.0% in the first quarter of 2026 and 10.9% in the second quarter of 2026. Each figure has a range, shown on the page.

Next: how we work
Method and sources

How this page was put together

The return figures on this page come from PPLI Vortex, the engine we built to work out hedge fund returns from SEC filings. For this fund it takes the long positions the manager reports each quarter on Form 13F, prices them through the following quarter, and scales the result to how hedge funds with a similar footprint have behaved, using publicly reported returns as calibration. It is not the return the fund reports to its investors, which also reflects shorts, derivatives, cash, trading within the quarter and fees. Fund facts come from Form ADV Schedule D, section 7.B.(1), and from Form D. Nothing here comes from the fund or its manager directly.

Form ADV usedFiled 28 March 2024
Form D used23 October 2026
13F quarter30 June 2026
EnginePPLI Vortex v12.4
CorrectionsWrite to the editor

The full methodology

For the fund and its manager

Do you run Emerging Markets Healthcare Partners? Help us get it right.

If you manage this fund or work for Exome Asset Management LLC, you can correct a fact, send us figures we do not have, such as audited returns, fees and terms, or point out a mistake. So can anyone else who spots one.

[email protected]

Please give the fund's name and its SEC private fund ID, 805-5624001535. We check what we receive against the filings, mark on the page what came from the manager, and publish any response you send, unedited.

Important information

Return figures on this page are estimates computed by PPLI.com from public regulatory filings using its PPLI Vortex engine. They are not reported, confirmed or audited by the fund, each is shown with a range and a confidence grade, and the true figures may differ materially from what investors received.

PPLI.com has no relationship with Emerging Markets Healthcare Partners or Exome Asset Management LLC, and neither has reviewed or approved this page. Facts are taken from filings with the U.S. Securities and Exchange Commission as of the dates shown and may since have changed. Holdings come from the manager's Form 13F, which covers all of its accounts and omits short positions, so they are not a statement of what this fund owns.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy an interest in any fund or insurance policy. Interests in private funds are offered only to eligible investors, by the fund's own offering documents. Past performance, estimated or reported, does not predict future results. The calculators are illustrations built on assumptions you can change. To report an error, write to the editor.

Full legal name Emerging Markets Healthcare Partners LLCSEC private fund ID 805-5624001535Updated 15 November 2026
Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.